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	 A	 series	 of	 new	 molecules	 having	 4‐substituted‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazin‐2‐
yl)methane	 substituted	 sulfonamide	 derivatives	 were	 synthesized.	 The	 structures	 of	 the
synthesized	compounds	were	elucidated	and	confirmed	by	1H	NMR,	13C	NMR,	Mass	spectra,
and	the	purity	was	checked	through	HPLC	analysis.	The	compounds	were	also	evaluated	for
their	 in	 vitro	 antiproliferative	 activity	 against	MCF‐7,	 HeLa,	 A‐549	 and	DU‐145	 cancer	 cell
lines	by	MTT	assay.	Compounds	4d,	7c	and	7d	were	tested	for	their	activity	against	a	panel	of
eight	human	kinase	at	10	µM	concentrations.	Among	them	the	compounds	4d	and	7d	showed
very	promising	activity	against	CDK5/P25	kinase	with	66	and	70%	inhibitions,	respectively.
Compound	7c	 also	 showed	promising	 activity	 of	 59%	 inhibition.	The	preliminary	 bioassay
showed	that	most	of	the	compounds	were	antiproliferative	with	different	degrees,	and	some
compounds	showed	better	activity	than	5‐fluorouracil	which	was	used	as	positive	control.	
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1.	Introduction	
	
Cancer	 is	 the	 major	 threat	 globally	 in	 20th	 century.	 Its	
treatment	 is	 difficult	 due	 to	 concerns	 about	 the	 toxicity	 and	
side	effects	[1].	Therefore,	a	good	deal	of	interest	has	develop‐
ped	 among	 the	medicinal	 chemists	 for	 the	 design,	 discovery	
and	 development	 of	more	 selective	 anticancer	 agents	 having	
fewer	side	effects	[2,3].	Various	types	of	anticancer	drugs	have	
diverse	 mechanism	 of	 action	 on	 the	 cancerous	 cells.	 Hence,	
finding	out	such	mechanisms	will	be	helpful	in	the	designing	of	
suitable	curative	remedy	for	attacking	the	cancerous	cells	[4].		
Here	we	 have	 chosen	 benzo[b][1,4]oxazinyl	 class	 for	 the	
synthesis	as	 these	derivatives	have	a	wide	range	of	biological	
activities	 like,	 treatment	of	 cardiovascular	 [5‐7],	 antibacterial	
[8,9],	 antifungal	 [10‐12],	 anticancer	 activity	 [13‐15]	 and	 pro‐
tein	methyl	transferases	inhibitors	[16].	Sulphonamide	deriva‐
tives	are	considered	as	an	important	moiety	in	drug	synthesis	
and	have	excellent	antimicrobial	activity	[17].		
Literature	survey	reveals	that	sulphonamide	bearing	drug	
molecules	like	dihydropyrazole	sulphonamide	derivatives	[18]	
and	 pyrazoline	 substituted	 benzenesulfonylureas	 [19]	 act	 as	
potential	 COX‐1/COX‐2	 inhibitors	 and	 antiproloferative	
agents,	 respectively.	 Our	 research	 group	 previously	 reported	
antimicrobial	and	anticancer	evaluation	for	new	derivatives	of	
thiazole,	piperidone	and	thiazolidinone	[20,21].		
Recent	 literature	reveals	 the	synthesis	of	1,4‐oxazine‐2‐yl	
derivatives	 in	water	 as	 green	solvent	 [22].	 In	 continuation	of	
our	 research	 and	 owing	 to	 the	 advantages	 of	 benzo[b][1,4]	
oxazinyl	 as	well	 as	 sulphonamide	moieties,	 we	 have	 synthe‐
sized	 new	 derivatives	 containing	 sulfonamide	 and	 benzo[b]	
[1,4]oxazinyl	in	one	frame	work.	The	synthetic	methods	adop‐
ted	 for	 the	 preparation	 of	 the	 4‐substituted‐3,4‐dihydro‐2H‐
benzo[b][1,4]	 oxazin‐2‐yl)methane	 substituted	 sulfonamide	
derivatives	 (4a‐e	 and	7a‐e)	 are	 depicted	 in	 Scheme	 1	 and	 2	
presented	 below.	 These	 derivatives	 are	 screened	 against	 a	
series	of	five	anticancer	cell	lines	and	some	were	tested	for	its	
activity	 against	 a	 panel	 of	 eight	 human	 kinase	 at	 10	 µM	
concentrations.	 By	 considering	 the	 biological	 importance	 of	
sulfonamides,	 we	 have	 synthesized	 series	 of	 compounds	
having	 4‐substituted‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazin‐2‐
yl)methane	substituted	sulfonamide	derivatives,	4a‐e	and	7a‐
e.	
	
2.	Experimental	
	
2.1.	Chemicals	and	instrumentation	
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Reagents	 and	 conditions:	 (a)	 2‐chloroacrylonitrile,	 CS2CO3,	 toluene,	 60	 °C,	 0.5	 h	 to	 110	 °C,	 4	 h;	 (b)	 benzyl	 bromide,	 2,6‐lutidine,	 DMAP,	 acetone,	 room	
temperature	to	80	°C,	1	h;	(c)	H2,	Raney	Ni,	methanolic	ammonia,	room	temperature;	(d)	substituted	sulfonyl	chlorides,	pyridine,	DCM,	room	temperature.	R1	=	
(a)	benzene	sulfonyl	chloride	(b)	4‐methyl	benzene	sulfonyl	chloride	(c)	4‐chloro	benzene	sulfonyl	chloride	(d)	4‐triflouromethyl	benzene	sulfonyl	chloride	(e)	
methyl	sulfonyl	chloride.	
	
Scheme	1
	
	
	
Reagents	and	conditions:	(a)	2‐chloromethylacrylonitrile,	CS2CO3,	toluene,	60	°C,	0.5	h	to	110	°C,	4	h;	(b)	phenylmethanethiol,	NaOH,	THF	room	temperature	to	
80	°C,	1	h;	(d)	Substituted	sulfonyl	chlorides,	pyridine,	DCM,	room	temperature.	R1	=	(a)	benzene	sulfonyl	chloride	(b)	4‐methyl	benzene	sulfonyl	chloride	(c)	4‐
chloro	benzene	sulfonyl	chloride	(d)	4‐triflouromethyl	benzene	sulfonyl	chloride	(e)	methyl	sulfonyl	chloride.	
	
Scheme	2	
	
	
All	chemicals,	unless	otherwise	specified,	were	purchased	
from	 commercial	 sources	 and	 were	 used	 without	 further	
purification.	The	major	chemicals	were	purchased	from	Sigma	
Aldrich	 and	 Avra	 Labs.	 The	 development	 of	 reactions	 was	
monitored	 by	 thin	 layer	 chromatography	 (TLC)	 analysis	 on	
Merck	pre‐coated	silica	gel	60	F254	aluminum	sheets,	visualized	
by	UV	 light.	All	 reactions	were	 carried	out	under	argon	 inert	
atmosphere.	 Melting	 points	 were	 recorded	 on	 SRS	 OptiMelt,	
melting	 point	 apparatus	 and	 are	 uncorrected.	 The	 purity	 of	
intermediates	 was	 assessed	 by	 TLC,	 NMR,	 and	 LC‐MS.	 The	
purities	of	final	compounds	were	assessed	by	NMR,	LC‐MS	and	
HPLC	 and	 all	 structures	 are	 consistent	with	 proposed	 struc‐
tures	characterization.	The	1H	NMR	spectra	were	recorded	on	
Varian	 NMR	 (400	 MHz)	 spectrometer.	 The	 13C	 NMR	 spectra	
were	 recorded	on	Varian	NMR	(100	MHz)	 spectrometer.	The	
chemical	 shifts	 are	 reported	 as	 NMR	 spectra	 δppm	 units.	 The	
following	 abbreviations	 are	 used;	 singlet	 (s),	 doublet	 (d),	
triplet	 (t),	 quartet	 (q),	 multiplet	 (m)	 and	 broad	 (br).	 Mass	
spectra	 were	 taken	 using	 Varian	 VG	 7070	 spectrometer	 at	
nominal	 5000	 resolution.	 Purity	 of	 final	 compounds	 were	
determined	 to	 be	 >95%	 by	 HPLC	 on	 an	 Alltech	 Alltima	 C18	
column	 (3.2	 ×	 150	 mm,	 5	 µM)	 eluting	 with	 5‐80%	 aceto‐
nitrile/45	nM	sodium	bicarbonate.		
	
2.2.	Synthesis	
	
2.2.1.	Synthesis	of	3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐2‐
carbonitrile	(1)	
To	 a	 stirred	 solution	 of	 2‐aminophenol	 (5	 g,	 45.8	mmol)	
was	 dissolved	 in	 toluene	 (50	 mL)	 then	 added	 cesium	
carbonate	(17.9	g,	55.0	mmol).	Stirred	reaction	mixture	at	60	
°C	 for	 0.5	 h	 then	 added	 2‐chloroacrylonitrile	 (4.79	 g,	 55.0	
mmol)	and	heat	reaction	mixture	at	110	°C	for	4	h.	Progress	of	
reaction	was	monitored	by	TLC.	After	completion	the	reaction,	
we	 evaporated	 reaction	 mixture	 under	 reduced	 pressure	 to	
obtain	 crude	 yellow	 gummy	 mass.	 Added	 H2O	 (50	 mL)	 and	
extracted	 it	 with	 ethyl	 acetate	 (EtOAc)	 (2	 ×	 50	 mL).	 The	
organic	 layer	 was	 separated,	 washed	with	 H2O	 (25	mL)	 and	
brine	(25	mL),	dried	over	anhydrous	Na2SO4	and	concentrated	
in	 vacuum.	 Purification	 of	 crude	 done	 by	 silica	 gel	 (100‐200	
mesh)	column	chromatography	by	using	EtOAc:hexane	(10:90,	
v:v)	 to	 obtain	 3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐2‐carbo‐
nitrile	(1)	(Scheme	1).	Color:	Yellow	solid.	Yield:	6.66	g,	90	%.	
MS	 (ESI,	m/z):	 161	 [M+H]+.	 1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	
ppm):	3.42	(dd,	1H,	J	=	12.8,	3.8	Hz,	NH‐CH2),	3.58	(dd,	1H,	J	=	
12.4,	 3.6	 Hz,	 NH‐CH2),	 5.57	 (s,	 1H,	 CN‐CH),	 6.19	 (s,	 1H,	 NH),	
6.58	(q,	1H,	Ar‐H),	6.64	(d,	1H,	J	=	8.82	Hz,	Ar‐H),	6.78	(q,	2H,	
Ar‐H).	1H	NMR	of	undesired	1a:	6.8‐6.78	(m,	2H),	6.61‐6.58	(m,	
2H),	5.61	(m,	1H),	4.38‐4.29	(q,	2H),	4.01	(br,	1H,	NH).	
	
2.2.2.	Synthesis	of	4‐benzyl‐3,4‐dihydro‐2H‐benzo[b][1,4]	
oxazine‐2‐carbonitrile	(2)	
	
To	a	stirred	solution	of	compound	1	(1.6	g,	10.0	mmol)	in	
acetone	 (32	mL)	was	 added	 2,6‐lutidine	 (2.14	 g,	 20.0	mmol)	
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and	dimethyl	aminopyridine	 (DMAP)	(0.24	g,	2.00	mmol)	 the	
mixture	was	stirred	at	room	temperature	for	15	min,	reaction	
mixture	 was	 cooled	 to	 0	 °C	 and	 1‐(bromomethyl)benzene	
(2.05	g,	12.0	mmol)	was	added	drop	wise	followed	by	stirring	
at	80	°C	 for	1	h.	The	reaction	was	monitored	by	TLC	and	LC‐
MS.	 After	 completion	 the	 reaction,	 the	 reaction	 mass	 was	
evaporated	 under	 reduced	 pressure	 to	 obtain	 crude	 gummy	
material.	The	reaction	mixture	was	diluted	with	H2O	(10	mL)	
and	extracted	with	dichloromethane	(DCM)	(2	×	10	mL).	The	
organic	layer	was	washed	with	aq.	saturated	NaHCO3	(15	mL),	
and	 brine	 (15	mL)	 solution.	 Separated	 the	 organic	 layer	 and	
dried	it	over	anhydrous	Na2SO4	and	evaporated	under	reduced	
pressure	 to	 get	 4‐benzyl‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazi	
ne‐2‐carbonitrile	(2).	The	product	was	confirmed	by	NMR	and	
LC‐MS	 and	 used	 as	 such	 for	 next	 step	 (Scheme	 1).	 Color:	
Yellow.	Yield:	2.25	g,	90	%.	MS	(ESI,	m/z):	251	[M+H]+.	1H	NMR	
(400	MHz,	 DMSO‐d6,	 δ,	 ppm):	 7.42‐7.18	 (m,	 5H,	 Ar‐H),	 6.83‐
6.79	(m,	2H,	Ar‐H),	6.63‐6.58	(m,	2H,	Ar‐H),	5.68	(m,	1H,	CN‐
CH),	4.42‐4.39	(q,	2H,	Ph‐CH2),	3.63‐3.57	(q,	2H,	N‐CH2).	
	
2.2.3.	Synthesis	of	(4‐benzyl‐3,4‐dihydro‐2H‐benzo[b][1,4]	
oxazin‐2‐yl)methanamine	(3)	
	
To	a	stirred	solution	of	compound	2	(0.25	g,	1.00	mmol)	in	
Parr	 shaker	 vessel	 added	methanolic	 ammonia	 (2.5	mL)	 and	
then	 added	 Raney	 Ni	 (0.05	 g)	 and	 kept	 reaction	 mixture	
hydrogen	gas	pressure	of	60	psi	 for	3	h.	Progress	of	 reaction	
was	monitored	by	TLC.	Filtered	reaction	mass	through	a	pad	of	
celite	 and	 obtain	 filtrate.	 Evaporated	 it	 under	 reduced	 pres‐
sure	 to	obtain	 crude	yellow	gummy	mass	which	was	washed	
by	EtOAc:hexane	mixture	(10:90,	v:v,	5	mL),	the	gummy	mass	
later	solidified	on	standing	and	obtain	(4‐benzyl‐3,4‐dihydro‐
2H‐benzo[b][1,4]oxazin‐2‐yl)methanamine	 (3)	 as	 a	 yellow	
solid	 (Scheme	1).	Color:	Yellow.	Yield:	0.22	g,	 85	%.	MS	 (ESI,	
m/z):	255	[M+H]+.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.38‐
7.28	 (m,	 5H,	Ar‐H),	 6.8‐6.73	 (m,	 2H,	Ar‐H),	6.64‐6.51	 (m,	 2H,	
Ar‐H),	5.48	(m,	1H,	CH2‐CH),	4.12‐4.10	(m,	2H,	Ph‐CH2),	3.63‐
3.57	(m,	2H,	N‐CH2),	3.15‐3.07	(m,	2H,	NH2‐CH2),	2.10	(br,	2H,	
CH2‐NH2).	
	
2.2.4.	General	procedure	for	the	synthesis	of	N‐((4‐benzyl‐
3,4‐dihydro‐2H‐benzo[b][1,4]oxazin‐2‐yl)methyl)‐4‐
substituted‐sulfonamide	derivatives	(4a‐4e)	
	
To	 a	 stirred	 solution	 compound	3	 (1	 equiv.)	 in	DCM	 (10	
times)	was	added	pyridine	(10	times)	the	mixture	was	stirred	
at	room	temperature	for	15	min.	Reaction	mixture	was	cooled	
to	 0	 °C	 and	 substituted	 sulfonyl	 chloride	 (1.2	 equiv.)	 was	
added	drop	wise	followed	by	stirring	at	room	temperature	for	
6	 h.	 The	 reaction	 was	 monitored	 by	 TLC	 and	 LC‐MS,	 after	
completion	 of	 reaction,	 the	 reaction	 mass	 was	 diluted	 with	
cold	 2	 N	 HCl	 and	 stirred	 it	 for	 30	 min.	 The	 precipitation	
formed	 in	 reaction	 mixture.	 Filtered	 the	 obtained	 solid	 and	
washed	it	with	excess	of	water	and	cold	diethyl	ether	and	cold	
pentane	 to	 obtain	 all	 compounds	 as	white	 solids.	 For	 filtrate	
extracted	with	DCM	twice.	The	organic	layer	was	washed	with	
brine	 solution;	 organic	 layer	 was	 evaporated	 under	 reduced	
pressure	 to	 get	 desired	 4‐substituted‐3,4‐dihydro‐2H‐benzo	
[b][1,4]oxazin‐2‐yl)methane	 substituted	 sulfonamide	 (4a‐e)	
derivatives	as	white	solids	(Scheme	1).		
N‐((4‐Benzyl‐3,	 4‐dihydro‐2H‐benzo[b][1,	 4]oxazin‐2‐yl)	
methyl)benzenesulfonamide	 (4a):	 Color:	 White.	 Yield:	 92%.	
M.p.:	175‐176	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.98	(t,	
1H,	J	=	6	Hz,	NH),	7.82‐7.80	(d,	2H,	J	=	6.8	Hz,	Ar‐H),	7.66‐7.57	
(m,	3H,	Ar‐H),	7.34‐7.24	(dd,	5H,	J	=	14.4,	6.8	Hz,		Ar‐H),	6.68‐
6.62	(m,	3H,	J	=	14.4,	7.8	Hz,	Ar‐H),	6.51	(q,	1H,	J	=	12.8,	6.8	Hz,	
Ar‐H),	4.48‐4.37	(q,	2H,	J	=	16.4,	11.6	Hz,	Ph‐CH2),	4.12	(m,	1H,	
CH2‐CH),	3.37	 (m,	1H,	N‐CH2),	 3.15‐3.12	 (m,	1H,	N‐CH2),	3.02	
(t,	2H,	J	=	6	Hz,	 	NH‐CH2).	13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	
145.12,	143.11,	140.38,	135.36,	129.2,	128.78,	128.12,	127.66,	
127.11,	 127.10,	 127.01,	 126.12,	 125.11,	 125.10,	 115.12,	
115.10,	110.22,	110.14,	80.30,	60.34,	55.12,	43.15.	MS	(EI,	m/z	
(%)):	395	(M+H).	HPLC:	Purity	=	98.0	%,	r.t.	=	7.98	min.		
N‐((4‐Benzyl‐3,	 4‐dihydro‐2H‐benzo[b][1,	 4]oxazin‐2‐yl)	
methyl)‐4‐methylbenzenesulfonamide	(4b):	Color:	White.	Yield:	
86%.	M.p.:	183‐184	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
7.88‐7.85	(t,	1H,	J	=	6	Hz,	NH),	7.70‐7.68	(d,	2H,	J	=	8	Hz,	Ar‐H),	
7.39‐7.37	 (d,	 2H,	 J	 =	 7.8	 Hz,	 Ar‐H),	 7.34‐7.30	 (m,	 2H,	 Ar‐H),	
7.26‐7.24	(m,	3H,	Ar‐H),	6.88‐6.63	(m,	3H,	Ar‐H),	6.51	(t,	1H,	J	
=	7.8	Hz,	Ar‐H),	4.48‐4.37	(q,	2H,	J	=	24.8,	8.0	Hz,	Ph‐CH2),	4.12	
(m,	 1H,	 CH2‐CH),	 3.37	 (m,	 1H,	 N‐CH2),	 3.17‐3.12	 (m,	 1H,	 N‐
CH2),	2.99	 (t,	 2H,	 J	 =	6	Hz,	NH‐CH2),	2.37	 (s,	 3H,	Ph‐CH3).	 13C	
NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	149.8,	145.5,	138.7,	135.1,	
133.4,	132.8,	130,	129.8,	129.2,	127.2,	126.0,	124.9,	124.1,	123,	
80.3,	60.34,	55.12,	43.18,	24.12.	MS	(EI,	m/z	(%)):	409	[M+H].	
HPLC:	Purity	=	97.4	%,	r.t.	=	8.18	min.		
N‐((4‐Benzyl‐3,	 4‐dihydro‐2H‐benzo[b][1,	 4]oxazin‐2‐yl)	
methyl)‐4‐chlorobenzenesulfonamide	 (4c):	 Color:	White.	 Yield:	
88%.	M.p.:	207‐208	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
8.08	(br,	1H,	NH),	7.82‐7.80	(d,	2H,	J	=	8.4	Hz,	Ar‐H),	7.67‐7.44	
(d,	2H,	J	=	8.4	Hz,	Ar‐H),	7.34‐7.24	(m,	5H,	Ar‐H),	6.70‐6.60	(m,	
3H,	Ar‐H),	6.51	 (t,	 1H,	 J	 =	7.2	Hz,	Ar‐H),	4.48‐4.37	 (q,	2H,	 J	 =	
16.2,	11.2	Hz,	Ph‐CH2),	4.12	(m,	1H,	CH2‐CH),	3.37	(m,	1H,	N‐
CH2),	3.30‐3.18	(m,	1H,	N‐CH2),	3.04	(d,	2H,	J	=	5.2	Hz,	NH‐CH2).	
13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	 145.12,	 143.11,	 140.38,	
137.68,	135.36,	129.2,	128.78,	127.66,	127.21,	127.11,	127.08,	
126.12,	125.11,	125.18,	115.12,	115.10,	110.22,	110.24,	80.30,	
60.34,	55.12,	43.14.	MS	(EI,	m/z	(%)):	429	[M+H].	HPLC:	Purity	
=	95.4	%,	r.t.	=	8.18	min.		
N‐((4‐Benzyl‐3,	 4‐dihydro‐2H‐benzo[b][1,	 4]oxazin‐2‐yl)	
methyl)‐4‐(trifluoromethyl)benzenesulfonamide	 (4d):	 Color:	
White.	Yield:	89%.	M.p.:	214‐215	°C.	1H	NMR	(400	MHz,	DMSO‐
d6,	δ,	ppm):	8.08	(br,	1H,	NH),	7.83‐7.61	(d,	2H,	J	=	8.4	Hz,	Ar‐
H),	7.66‐7.44	(d,	2H,	J	=	8.4	Hz,	Ar‐H),	7.34‐7.29	(m,	5H,	Ar‐H),	
6.71‐6.61	(m,	3H,	Ar‐H),	6.51	(m,	1H,	Ar‐H),	4.48‐4.37	(q,	2H,	J	
=	17.2,	11.0	Hz,	Ph‐CH2),	4.10	(m,	1H,	CH2‐CH),	3.37	(m,	1H,	N‐
CH2),	3.30‐3.18	(m,	1H,	N‐CH2),	3.06	(t,	2H,	J	=	5.4	Hz,	NH‐CH2).	
13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	 145.12,	 143.11,	 140.38,	
135.36,	 134.44,	 129.24,	 128.88,	 128.12,	 127.66,	 127.11,	
127.14,	 127.01,	 126.12,	 125.11,	 125.10,	 115.12,	 115.10,	
110.22,	 110.14,	 80.30,	60.34,	55.22,	43.14.	MS	 (EI,	m/z	 (%)):	
462	[M+H].	HPLC:	Purity	=	97.4	%,	r.t.	=	8.28	min.		
N‐((4‐Benzyl‐3,	 4‐dihydro‐2H‐benzo[b][1,	 4]oxazin‐2‐yl)	
methyl)methanesulfonamide	 (4e):	 Color:	 Yellow.	 Yield:	 81%.	
M.p.:	135‐136	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.35‐
7.23	(m,	6H,	Ar‐H),	6.74‐6.67	(m,	3H,	Ar‐H),	6.54	(t,	1H,	J	=	6.4	
Hz,	NH),	4.53‐4.42	(q,	2H,	J	=	15.6,	8.8	Hz,	Ph‐CH2),	4.20	(m,	1H,	
CH2‐CH),	 3.42‐3.37	 (m,	 1H,	 N‐CH2),	 3.21‐3.16	 (m,	 3H,	 N‐CH2,	
NH‐CH2),	 2.94	 (s,	 3H,	 S‐CH3).	 13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	
ppm):	145.12,	143.11,	140.38,	135.36,	128.78,	128.12,	127.66,	
127.01,	 126.12,	 115.12,	 115.10,	 110.22,	 110.14,	 80.3,	 60.34,	
55.12,	43.15,	41.21.	MS	(EI,	m/z	(%)):	333	[M+H].	HPLC:	Purity	
=	97.4	%,	r.t.	=	7.20	min.		
	
2.2.5.	Synthesis	of	2‐(chloromethyl)‐3,4‐dihydro‐2H‐benzo	
[b][1,4]oxazine	(5)	
	
To	 a	 stirred	 solution	 of	 2‐aminophenol	 (5	 g,	 45.8	mmol)	
was	 dissolved	 in	 toluene	 (50	mL)	 then	 added	 cesium	 carbo‐
nate	(18.7	g,	57.4	mmol).	Stirred	reaction	mixture	at	60	°C	for	
0.5	 h	 then	 added	 2‐chloromethylacrylo	 nitrile	 (5.79	 g,	 57.4	
mmol)	 and	 heat	 reaction	 mixture	 at	 110	 °C	 for	 4	 h.	 After	
completion	 the	 raection,	 we	 evaporated	 reaction	 mixture	
under	reduced	pressure	to	obtain	crude	yellow	gummy	mass.	
Added	H2O	(50	mL)	and	extracted	it	with	EtOAc	(2	×	50	mL).	
The	 organic	 layer	 was	 separated,	 washed	with	 H2O	 (25	mL)	
and	brine	(25	mL),	dried	over	anhydrous	Na2SO4	and	concent‐
rated	in	vacuum.	Purification	of	crude	done	by	silica	gel	(100‐
200	 mesh)	 column	 chromatography	 by	 using	 EtOAc:hexane	
(90:10,	v:v)	 to	obtain	3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐2‐
carbonitrile	(5)	(Scheme	2).	Color:	Yellow.	Yield:	87	%.	MS	(EI,	
m/z	(%)):	184	[M+H]+.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
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6.80‐6.71	(m,	2H,	Ar‐H),	6.60‐6.54	(m,	2H,	Ar‐H),	5.31	(m,	1H,	
CH2‐CH),	4.01	(br,	1H,	NH),	3.83‐3.61	(m,	4H,	CH‐CH2,	Cl‐CH2).	
	
2.2.6.	Synthesis	of	2‐((benzylthio)methyl)‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine	(6)	
	
To	a	stirred	solution	of	compound	5	(0.36	g,	2.00	mmol)	in	
THF	 (10	 mL)	 was	 added	 NaOH	 (0.08	 g,	 2.00	 mmol)	 and	
mixture	 was	 stirred	 at	 room	 temperature	 for	 15	 min.	 The	
reaction	mixture	was	 cooled	 to	0	 °C	 and	phenylmethanethiol	
(0.29	g,	2.40	mmol)	was	added	drop	wise	followed	by	stirring	
at	80	°C	 for	1	h.	The	reaction	was	monitored	by	TLC	and	LC‐
MS,	after	completion	of	reaction,	we	evaporated	reaction	mass	
under	reduced	pressure	to	obtain	crude	gummy	material.	The	
reaction	mixture	was	diluted	with	H2O	(10	mL)	and	extracted	
with	DCM	(2	×	10	mL).	The	organic	layer	was	washed	with	sat.	
NaHCO3	solution	(10	mL),	and	brine	solution	(10	mL),	organic	
layer	 was	 dried	 over	 anhydrous	 Na2SO4	 and	 concentrated	 in	
vacuum	 to	 obtain	 2‐((benzylthio)methyl)‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine	 (6).	 The	 product	was	 confirmed	 by	 LC‐
MS	and	used	as	such	for	next	step	(Scheme	2).	Color:	Yellow.	
Yield:	85	%.	MS	(EI,	m/z	(%)):	272	[M+H]+.	1H	NMR	(400	MHz,	
DMSO‐d6,	 δ,	ppm):	7.38‐7.20	(m,	5H,	Ar‐H),	6.83‐6.78	(m,	2H,	
Ar‐H),	6.61‐6.58	(m,	2H,	Ar‐H),	5.31	(m,	1H,	CH2‐CH),	4.01	(br,	
1H,	NH),	3.81‐3.60	(m,	4H,	NH‐CH2,	Ar‐CH2),	2.94‐2.74	(m,	2H,	
S‐CH2).	
	
2.2.7.	General	procedure	for	the	synthesis	of	2‐((benzylthio)	
methyl)‐3,4‐dihydro‐4‐substituted‐2H‐benzo[b][1,4]oxazine	
(7a‐7e)	
	
To	a	stirred	solution	of	compound	6	(1	equiv.)	in	DCM	(10	
times)	was	added	pyridine	(10	times)	the	mixture	was	stirred	
at	room	temperature	for	15	min.	Reaction	mixture	was	cooled	
to	 0	 °C	 and	 substituted	 sulfonyl	 chloride	 (1.2	 equiv.)	 was	
added	drop	wise	followed	by	stirring	at	room	temperature	for	
6	 h.	 The	 reaction	 was	 monitored	 by	 TLC	 and	 LC‐MS,	 after	
completion	of	reaction	mass	was	diluted	with	cold	2	N	HCl	and	
stirred	 it	 for	 30	 min.	 The	 precipitation	 formed	 in	 reaction	
mixture.	Filtered	the	obtained	solid	and	washed	it	with	excess	
of	water	and	cold	diethyl	ether	and	cold	pentane	to	obtain	all	
compounds	 as	 white	 solids.	 For	 filtrate	 extracted	 with	 DCM	
twice.	 The	 organic	 layer	 was	 washed	 with	 brine	 solution;	
organic	 layer	was	 evaporated	 under	 reduced	 pressure	 to	 get	
desired	 2‐((benzylthio)methyl)‐3,4‐dihydro‐4‐substituted‐2H‐
benzo[b][1,4]oxazine	derivatives	(7a‐e)	(Scheme	2).	
2‐((Benzylthio)methyl)‐4‐(phenylsulfonyl)‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine	(7a):	Color:	White.	Yield:	95%.	M.p.:	164‐
165	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.90	(d,	2H,	J	=	
7.6	Hz,	Ar‐H),	7.64‐7.58	(d,	1H,	J	=	7.2	Hz,	Ar‐H),	7.56‐7.55	(m,	
2H,	Ar‐H),	7.31‐7.27	(m,	2H,	J	=	6.8	Hz,	Ar‐H),	7.24‐7.20	(m,	3H,	
Ar‐H),	 6.68‐6.60	 (m,	 2H,	Ar‐H),	6.62	 (t,	 1H,	 J	=	8.0	Hz,	Ar‐H),	
6.51	(t,	1H,	J	=	7.2	Hz,	Ar‐H),	4.12	(m,	2H,	CH2‐CH,	S‐CH2),	4.08	
(q,	1H,	S‐CH2),	3.32‐3.29	(dd,	1H,	N‐CH2),	3.12‐3.09	(m,	1H,	N‐
CH2),	2.99	(d,	2H,	J=	6	Hz,	CH‐CH2).	13C	NMR	(100	MHz,	CDCl3,	
δ,	ppm):	141.12,	140.11,	139.38,	135.36,	129.2,	128.78,	128.12,	
127.66,	 127.11,	 127.10,	 127.01,	 126.12,	 125.11,	 125.10,	
115.12,	115.10,	110.22,	110.14,	78.30,	54.12,	38.15,	38.10.	MS	
(EI,	m/z	 (%)):	 412	 [M+H].	HPLC:	 Purity	 =	 98.0	%,	 r.t.	 =	 8.12	
min.		
2‐((Benzylthio)methyl)‐4‐tosyl‐3,	4‐dihydro‐2H‐benzo[b]	 [1,	
4]oxazine	(7b):	Color:	White.	Yield:	94%.	M.p.:	169‐170	°C.	1H	
NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 7.72‐7.68	 (d,	 4H,	 Ar‐H),	
7.39‐7.37	 (d,	 2H,	 J	 =	 8.4	 Hz,	 Ar‐H),	 7.34‐7.30	 (m,	 2H,	 Ar‐H),	
7.26‐7.24	(m,	1H,	Ar‐H),	6.88‐6.63	(m,	3H,	Ar‐H),	6.51	(t,	1H,	J	
=	 6.2	 Hz,	 Ar‐H),	 4.12	 (m,	 2H,	 CH2‐CH,	 S‐CH2),	 4.06	 (q,	 1H,	 S‐
CH2),	3.36‐3.32	(dd,	1H,	N‐CH2),	3.18‐3.08	(m,	1H,	N‐CH2),	2.98	
(d,	 J=6	 Hz,	 2H,	 CH‐CH2),	 2.37	 (s,	 3H,	 Ar‐CH3).	 13C	 NMR	 (100	
MHz,	 CDCl3,	 δ,	 ppm):	 141.22,	 140.11,	 139.48,	 135.36,	 129.22,	
128.22,	127.66,	127.11,	127.10,	127.01,	126.12,	125.11,	125.1,	
115.12,	 115.10,	 110.22,	 110.14,	 78.31,	 54.12,	 38.14,	 38.11,	
23.64.	MS	(EI,	m/z	(%)):	426	[M+H].	HPLC:	Purity	=	98.4	%,	r.t.	
=	7.17	min.		
2‐((Benzylthio)methyl)‐4‐((4‐chlorophenyl)sulfonyl)‐3,	 4‐di	
hydro‐2H‐benzo[b][1,4]oxazine	 (7c):	Color:	White.	Yield:	87%.	
M.p.:	181‐182	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.79‐
7.71	(d,	2H,	J	=	8.4	Hz,	Ar‐H),	7.62‐7.60	(d,	2H,	J	=	8.4	Hz,	Ar‐H),	
7.31‐7.27	(m,	2H,	Ar‐H),	7.23‐7.19	(m,	3H,	Ar‐H),	6.67‐6.64	(m,	
1H,	Ar‐H),	6.58	(d,	2H,	J	=	9.2	Hz,	Ar‐H),	6.49	(t,	1H,	J	=	7.2	Hz,	
Ar‐H),	4.35	 (m,	2H,	CH2‐CH,	S‐CH2),	4.08	 (q,	1H,	S‐CH2),	3.30‐
3.28	(dd,	1H,	N‐CH2),	3.14‐3.08	(m,	1H,	N‐CH2),	3.03	(d,	2H,	J	=	
4.4	Hz,	 CH‐CH2).	 13C	NMR	 (100	MHz,	 CDCl3,	 δ,	 ppm):	 141.12,	
140.21,	 139.38,	 135.36,	 129.26,	 128.78,	 128.72,	 127.66,	
127.11,	 127.10,	 127.01,	 126.12,	 125.11,	 125.10,	 115.12,	
115.10,	110.22,	110.14,	78.31,	54.12,	38.25,	38.11.	MS	(EI,	m/z	
(%)):	447	[M+H].	HPLC:	Purity	=	97.4	%,	r.t.	=	8.12	min.		
2‐((Benzylthio)methyl)‐4‐((4‐(trifluoromethyl)phenyl)	 sul‐
fonyl)‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine	 (7d):	 Color:	White.	
Yield:	86%.	M.p.:	191‐192	°C.	 1H	NMR	(400	MHz,	DMSO‐d6,	δ,	
ppm):	7.80‐7.71	(d,	2H,	J	=	8.4	Hz,	Ar‐H),	7.66‐7.44	(d,	2H,	J	=	
8.4	Hz,	Ar‐H),	7.41‐7.37	(m,	2H,	Ar‐H),	7.21‐7.18	(m,	3H,	Ar‐H),	
6.67‐6.64	(m,	2H,	Ar‐H),	6.58	(d,	1H,	J	=	9.2	Hz,	Ar‐H),	6.49	(t,	
1H,	J	=	7.2	Hz,	Ar‐H),	4.33	(m,	2H,	CH2‐CH,	S‐CH2),	4.06	(q,	1H,	
S‐CH2),	 3.32‐3.28	 (dd,	 1H,	 N‐CH2),	 3.16‐3.07	 (m,	 1H,	 N‐CH2),	
3.02	(d,	2H,	 J	=	4.4	Hz,	CH‐CH2).	 13C	NMR	(100	MHz,	CDCl3,	δ,	
ppm):	141.12,	140.10,	139.48,	135.26,	129.26,	128.78,	128.22,	
127.66,	 127.11,	 127.10,	 127.01,	 126.12,	 125.26,	 125.11,	
125.10,	 115.12,	 115.10,	 110.22,	 110.14,	 78.31,	 54.12,	 38.15,	
38.11.	MS	(EI,	m/z	(%)):	480	[M+H].	HPLC:	Purity	=	98.4	%,	r.t.	
=	8.38	min.		
2‐((Benzylthio)methyl)‐4‐(methylsulfonyl)‐3,	 4‐dihydro‐2H‐
benzo[b][1,4]oxazine	(7e):	Color:	Yellow.	Yield:	81%.	M.p.:	127‐
128	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.30‐7.18	(br	m,	
5H,	Ar‐H),	6.74‐6.67	(m,	3H,	Ar‐H),	6.54	(t,	1H,	Ar‐H),	4.46‐4,32	
(m,	2H,	CH2‐CH,	S‐CH2),	4.16	(q,	1H,	S‐CH2),	3.36‐3.33	(dd,	1H,	
N‐CH2),	3.19‐3.13	(m,	3H,	N‐CH2,	CH‐CH2),	2.89	(s,	3H,	S‐CH3).	
13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	 141.12,	 140.11,	 139.38,	
135.36,	 129.20,	 128.78,	 128.12,	 127.10,	 127.01,	 125.10,	
115.12,	 115.10,	 110.22,	 110.14,	 78.3,	 54.12,	 38.15,	 38.10,	
37.28.	MS	(EI,	m/z	(%)):	350	[M+H].	HPLC:	Purity	=	98.4	%,	r.t.	
=	7.64	min.		
	
2.3.	Anticancer	activity	
	
All	 the	 synthesized	 compounds	 were	 tested	 for	 their	 in	
vitro	anticancer	activity	against	A‐549‐Human	lung	cancer	cell	
line,	 HeLa‐Human	 cervical	 cancer	 cell	 line,	 MCF‐7‐Human	
breast	cancer	cell	line,	DU‐145‐Human	prostate	cancer	cell	line	
and	 HUVEC‐Human	 umbilical	 vein	 endothelial	 cell	 line.	 The	
anticancer	 activity	 test	 is	 performed	 according	 to	 the	
procedure	 developed	 by	 the	 National	 Cancer	 Institute	 (NCI,	
USA)	 in	 the	 ‘In	 vitro	Anticancer	 Drug	 Discovery	 Screen’	 that	
uses	 the	 protein‐binding	 dye	 Sulforhodamine	 B	 (SRB)	 to	
assess	 cell	 growth	 [23,24].	 Briefly,	 cells	 are	 grown	 in	96‐well	
plates	 in	 suspension	 and	 then	were	 exposed	 for	 48	 hours	 to	
four	serial	concentrations	of	1×10‐7,	1×10‐6,	1×10‐5,	1×10‐4	and	
1×10‐3	M	 of	 each	 compound.	 Following	 this,	 cells	were	 fixed	
and	 stained	 with	 protein	 binding	 SRB	 stain.	 Excess	 stain	 is	
washed	and	bound	stain	was	solubilized,	 and	 the	absorbance	
was	measured	 at	 492	nm	 in	 a	 plate	 reader.	 Concentration	of	
the	 compounds	 that	 inhibited	 50%	 of	 the	 net	 cell	 growth,	
growth	inhibition	of	50%	(GI50),	was	calculated	from	the	dose	
response	curve	obtained	for	each	test	compound	and	cell	line.	
GI50	values	were	presented	in	micro	molar	(μM)	concentration.	
5‐Flourouracil	 (5‐Fu)	 was	 used	 as	 positive	 control	 for	 the	
comparison	of	cytotoxicity	of	synthesized	compounds.	Assays	
were	 performed	 in	 triplicate	 on	 three	 independent	
experiments	 and	 their	 mean	 values	 are	 taken	 as	 a	 final	
reading.	 All	 experiments	 were	 performed	 in	 duplicate	 and	
repeated	three	times.	
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Table	1.	Screening	conditions	for	Step	(a)	in	Scheme	1	and	2.	
Entry	 Base	(3	equiv.)	 Solvent	 Temperature	(°C)	 Time	(h)	 Yield	(%)	a,	Compound	1	and	1a		
1	 K2CO3	 Acetone	 70 12 35,	25
2	 K2CO3	 DMF	 110	 12	 25,	32	
3	 K2CO3	 Toluene	 100	 12	 40,	36	
4	 Cs2CO3	 Acetone	 70 12 45,	25
5	 Cs2CO3	 DMF	 110	 12	 40,	29	
6	 Cs2CO3	 Toluene	 110	 12	 70,	10	
7	 KOtBu	 DMF	 110 12 37,	25
8	 KOtBu	 Toluene	 110 12 35,	38
9	 Na2CO3	 DMF	 110 12 20,	45
10	 Na2CO3	 Toluene	 110 12 25,	51
11	 K3PO4	 DMF	 110 12 45,	30
12	 K3PO4	 Toluene	 110 12 35,	31
a	Isolated	yield.	
	
	
	
The	1H	NMR	of	compound	1	shows	protons	at	3.42	(dd,	1H,	J	=	12.8,	3.8	Hz,	NH‐CH2),	3.58	(dd,	1H,	J	=	12.4,	3.6	Hz,	NH‐CH2),	5.57	(s,	1H,	CN‐CH),	6.19	(s,	1H,	
NH),	6.58	(q,	1H,	Ar‐H),	6.64	(d,	1H,	J	=	8.82	Hz,	Ar‐H),	6.78	(q,	2H,	Ar‐H).	
	
Scheme	3
	
3.	Results	and	discussion	
	
3.1.	Synthesis	
	
The	synthetic	methods	adopted	for	the	preparation	of	the	
title	compounds	4a‐e	and	7a‐e	is	depicted	in	the	Scheme	1	and	
2	 presented	 below.	 An	 initial	 investigation	 of	 reaction	
conditions	 for	 Step	 (a)	was	 done	 by	 using	 2‐aminophenol	 (1	
equiv.)	 react	 with	 2‐chloroacrylonitrile	 (1.2	 equiv.)	 and	 2‐
chloromethylacrylonitrile	(1.2	equiv.)	by	using	different	bases,	
solvents	and	temperature.	The	results	are	tabulated	in	Table	1.	
We	 have	 screened	 K2CO3	 in	 entry	 1,	 2	 and	 3	 by	 taking	
solvents	 acetone	 DMF	 and	 toluene	 for	 70,	 110	 and	 100	 °C,	
respectively	for	12	h	(For	entry	1	and	4,	we	have	used	chilled	
water	 circulation).	 After	 column	 purification,	 we	 have	
obtained	desired	product	 in	35,	25	 and	40%,	 respectively.	 In	
entry	 4,	 5	 and	 6,	 we	 have	 used	 Cs2CO3	 in	 acetone	 DMF	 and	
toluene	to	obtain	yields	from	45,	40	and	70%,	respectively.	In	
conditions	 7	 to	 12,	 we	 have	 used	 potassium	 tert	 butoxide	
(KOtBu),	Na2CO3	and	K3PO4	in	DMF	and	toluene	as	solvents	the	
yields	are	 in	 the	 range	of	20	 to	45%.	With	K3PO4	 the	yield	of	
compound	1	and	1a	is	like	60	to	40%,	respectively,	so,	it	is	not	
favorable	 and	 that	 of	 Na2CO3	 the	 undesired	 compound	1a	 is	
major	 isolated	 compound	 compared	 to	 desired	 isolated	
compound	1,	confirmed	from	entries	9	to	12.	
In	 all	 conditions,	 there	 is	 formation	 of	 two	merged	 spots	
among	 them	one	 is	product	 and	one	 is	 side	product	which	 is	
confirmed	by	separating	them.	Both	compounds	are	eluting	at	
same	 polarity	 of	 EtOAc:hexane	 (10:90,	 v:v)	 from	 column	
chromatography.	 We	 have	 isolated	 both	 compounds	 by	
column	 chromatography	 by	 using	 silica	 gel	 (100‐200	 mesh)	
and	 confirmed	 the	 structure	 of	 compound	 1	 by	 the	 help	 of	
Nuclear	 Overhauser	 Effect	 (NOE)	 experiments	 there	 results	
are	depicted	in	Scheme	3.	
From	 first	 NOE	 experiment	 on	 compound	 1,	 we	 have	
irradiated	proton	at	δ	5.57	ppm,	both	 the	protons	of	NH‐CH2	
shows	signals	at	δ	3.58	(weak)	and	3.42	ppm	(strong)	because	
proton	at	δ	3.58	ppm	is	above	the	plane	and	proton	of	δ	3.42	
ppm	 below	 the	 plane.	 In	 second	 NOE	 experiment,	 we	 have	
irradiated	proton	at	δ	6.19	ppm	(‐NH),	one	aromatic	proton	at	
δ	 6.64	 ppm	 next	 	 to	 ‐NH	 shows	 signal	 along	 with	 δ	 3.58	
(strong)	 and	 3.42	 ppm	 (weak)	 	 as	 ‐NH	 and	 ‐NH‐CH2	 protons	
are	 in	 different	 planes.	 In	 third	 NOE	 experiment,	 we	 have	
irradiated	proton	at	δ	3.58	ppm	of	(‐NH‐CH2)	protons	at	δ	3.42	
ppm	shows	signal	along	with	δ	6.19	and	5.57	ppm	as	both	of	
these	 are	 adjacent	 to	 (‐NH‐CH2)	 protons.	 From	 above	 three	
NOE	experiments	confirms,	compound	1	as	desired	product.	In	
all	optimization	reactions	major	side	product	is	compound	1a,	
with	the	yields	of	10	to	51%.	In	entry	6,	when	we	use	Cs2CO3		
with	 toluene	 at	 110	 °C	 for	 12	 h,	 there	 is	 70%	 formation	 of	
product	1	and	10%	formation	of	compound	1a.	
Further,	 we	 have	 explored	 this	 condition	 to	 increase	 the	
yield	 of	 compound	 1.	 We	 have	 modified	 condition	 by	 pre‐
paring	anion	by	heating	2‐amino	phenol	with	Cs2CO3	at	60	°C	
for	 0.5	 h	 then	 adding	 the	 2‐chloroacrylonitrile	 and	 further	
heating	at	110	°C	for	4	h	there	is	90%	formation	of	compound	
1	and	3%	formation	of	compound	1a.	For	Step	(a)	in	Scheme	2,	
we	treated	2‐amino	phenol	with	Cs2CO3	at	60	°C	for	0.5	h	then	
adding	the	2‐chloromethylacrylonitrile	and	 further	heating	at	
110	°C	for	4	h,	there	is	87%	formation	of	compound	5	and	5%	
formation	of	compound	1a.	
For	 Step	 (b),	 again,	 we	 have	 optimized	 the	 condition	 as	
mentioned	in	Table	2	by	taking	compound	1	and	5	 (1	equiv.)	
and	 reacting	 it	with	benzyl	 bromide	 and	phenylmethanethiol	
(1.2	equiv.)	each.	
We	 have	 optimized	 base,	 solvents,	 temperature	 and	 time	
for	getting	better	yields	for	Step	(b).	All	reactions	were	initially	
done	from	0	°C	to	room	temperature	for	6	h	(Table	2,	Entries	1	
to	5)	on	TLC,	there	is	majority	of	starting	remains	as	such	then	
we	applied	heating	them	for	remaining	time	at	70	°C	the	yields	
are	 in	 between	 20‐60%.	 But,	 in	 entries	 6	 and	 7,	 we	 directly	
heated	 reaction	 mixture	 for	 4	 h	 the	 yield	 obtained	 of	 the	
product	was	60	and	55%,	respectively.		
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Table	2.	Screening	conditions	for	Step	(b)	in	Scheme	1.	
Entry	 Base	 Solvent	 Temperature	(°C)	 Time	(h)	 Yield	(%)	a,	Compound	2	and	6		
1	 TEA	 THF	 0		to	70	 12 30,	15
2	 Pyridine	 THF	 0		to	70 8 25,	NA
3	 DIPEA	 THF	 0		to	70	 12 20,	NA
4	 2,6‐Lutidine	 THF	 0		to	70	 12 25,	8
5	 2,6‐Lutidine	 DMF	 0		to	70		 12	 40,	15	
6	 2,6‐Lutidine+DMAP	 Acetone	 0		to	70		 4	 60,	20	
7	 2,6‐Lutidine+DMAP	 Acetone	 0		to	70	 4 55,	16
8	 2,6‐Lutidine+DMAP	 Acetone	 0		to	80		 1	 85,	21	
a	Isolated	yield.	
	
Table	3.	In	vitro	anticancer	screening	of	the	synthesized	compounds	against	five	cell	lines.		
Compound	 A‐549	a	 SIf	 HeLa	b	 SI	f MCF‐7	c SI	f DU‐145	d SI	f	 HUVEC	e
4a	 22.72±0.11	 4.03	 23.87±0.08	 3.83	 24.12±0.06	 3.79	 28.86±0.22	 3.17	 91.6±0.28	
4b	 33.81±0.11	 2.94	 24.32±0.04 4.09 25.32±0.06 3.93 23.73±0.12 4.19	 99.6±0.14
4c	 10.81±0.11	 8.85	 28.32±0.04	 3.37	 27.32±0.06	 3.50	 20.73±0.12	 4.61	 95.7±0.28	
4d	 10.65±0.11	 8.78	 10.79±0.22	 8.67	 12.86±0.12	 7.27	 10.82±0.11	 8.65	 93.6±0.28	
4e	 23.86±0.08	 3.96	 14.38±0.06 6.57 23.63±0.12 4.00 21.52±0.22 4.39	 94.6±0.12
7a	 25.72±0.11	 3.71	 26.87±0.08 3.55 24.12±0.06 3.96 28.86±0.22 3.31	 95.6±0.28
7b	 33.82±0.11	 2.61	 21.99±0.22 4.00 20.36±0.12 4.35 22.52±0.11 3.93	 88.6±0.28
7c	 10.78±0.14	 9.23	 10.78±0.08 9.23 13.82±0.08 7.20 14.72±0.06 6.76	 96.6±0.19
7d	 10.82±0.11	 9.15	 10.99±0.22 9.01 12.36±0.12 8.01 19.52±0.11 5.07	 99.1±0.26
7e	 24.13±0.12	 3.71	 25.16±0.08 3.56 26.12±0.12 3.43 21.62±0.11 4.14	 89.6±0.22
5‐FU	 1.71±0.11	 46.54	 1.82±0.13 43.73 1.91±0.08 41.67 1.82±0.08 43.73	 79.6±0.18
a	A‐549:	Human	lung	cancer	cell	line.	
b	HeLa:	Human	cervical	cancer	cell	line	(ATCC	CCL‐2).	
c	MCF‐7:	Human	breast	cancer	cell	line.	
d	DU‐145:	Human	prostate	cancer	cell	line.	
e	HUVEC:	Human	umbilical	vein	endothelial	cell	line	(ATCC	CRL‐1730).	
f	Selectivity	Index	(SI)=	IC50	of	pure	compound	in	normal	cell	line/IC50	of	same	compound	in	cancer	cell	line;	IC50:	The	concentration	required	to	inhibit	50%	of	
cell	population.	
	
	
In	 entries	6	 and	7,	we	have	used	DMAP	as	 an	additive	 in	
ratio	of	(For	entry	6,	1	equiv.	2,6	leutidine	:	1	equiv.	DMAP;	and	
for	 entry	7,	 1	 equiv.	2,6‐leutidine	 :	 0.5	 equiv.	DMAP)	 interes‐
tingly	 yield	 is	 increased.	 Further,	 we	 have	 modified	 the	
conditions	in	entry	8.	In	entry	8,	we	have	used	2	equiv.	of	2,6‐
lutidine	and	0.2	 equiv.	of	DMAP,	 the	obtained	yield	was	85%	
after	 direct	 heating	 the	 reaction	mixture	 at	 80	 °C	 for	 1	 h	 by	
using	chilled	water	circulating	condenser	we	obtain	yield	85%	
in	 Scheme	 1.	 In	 Scheme	 2,	 for	 step	 b,	 all	 the	 conditions	
mentioned	in	Table	2	are	failed	to	give	good	yields	so	need	to	
modify	the	condition	for	synthesis	of	compound	6.		
We	 have	 modified	 conditions	 (Step	 (b),	 Scheme	 2)	 for	
phenylmethanethiol	by	changing	base	as	sodium	hydroxide	in	
THF	and	heating	at	80	°C	for	1	h	to	obtain	the	desired	product	
in	 87%	 yield	which	 is	 used	 further	 for	 sulfonamide	 coupling	
reaction.	We	have	modified	the	base	and	we	got	the	yield	87%	
without	 purification	 which	 is	 used	 further	 for	 synthesis	 of	
compounds	 7a‐e.	 During	 synthesis	 of	 compound	 6	 by	 using	
Table	2	conditions,	we	got	sluggish	reaction	mixture	which	is	
difficult	 to	 purify	multiple	 spots	 on	 TLC	 and	 LC‐MS	 showing	
multiple	unidentified	masses	so	we	modified	the	conditions	b	
in	Scheme	2	for	synthesis	of	compound	6.	
For	 Step	 (c)	 (Scheme	 1),	 we	 have	 used	 Raney	 Ni	 with	
hydrogen	 gas	 pressure	 of	 60	 psi	 in	 Parr	 shaker	 in	 saturated	
methanolic	ammonia	for	3	h	at	room	temperature;	it	gives	the	
best	results	and	yield	obtained	is	85%.	For	Step	(d)	(Scheme	1	
and	 2),	we	 have	 used	 1:1	mixture	 of	 DCM	 and	 pyridine	 as	 a	
solvent	and	base	to	get	yields	ranging	from	80‐95%	for	all	the	
compounds	4a‐e	and	7a‐e.	
	
3.2.	Anticancer	activity	
	
All	the	newly	synthesized	compounds	4a‐e	and	7a‐e	were	
evaluated	 for	 their	 antiproliferative	 activities	 against	 a	 panel	
of	 four	 different	 human	 cancer	 cell	 lines.	 The	 IC50	 for	 each	
synthesized	 compounds	 are	 calculated	 with	 respect	 to	 one	
human	normal	cell	 line	Human	umbilical	vein	endothelial	cell	
line	(ATCC	CRL‐1730)	and	results	are	summarized	in	Table	3.	
These	 values	 represent	 the	 concentration	 required	 to	 inhibit	
50%	 cell	 population	 compared	with	 the	 control	 cells	 treated	
with	 DMSO	 and	 positive	 control	 5‐fluorouracil	 under	 similar	
conditions.	From	compounds	4a‐4e,	the	IC50	value	ranges	from	
10.65	 to	 33.81	 µM	 all	 four	 cell	 lines.	 For	 cell	 line	 A‐549	
compound	4c	 is	most	 active	with	 IC50	value	of	10.65	µM	and	
compound	 4d	 is	 also	 active	 with	 IC50	 value	 of	 10.81	 µM.	
Compound	4b	 is	very	 less	active	with	 IC50	value	of	33.81	µM.	
Similar	 results	 are	 obtained	 with	 remaining	 cell	 lines.	
Compound	4d	having	IC50	values	of	10.79,	12.86	and	10.82	µM	
in	 HeLa,	 MCF‐7	 and	 DU‐145	 cell	 lines,	 respectively.	 The	
compound	4c	 is	active	in	A‐549	only,	 it	 is	 less	active	 in	HeLa,	
MCF‐7	 and	DU‐145	 cell	 lines	with	 IC50	 values	 of	 28.32,	 27.32	
and	 20.73	 µM,	 respectively.	 The	 compounds	 7a‐e	 the	 IC50	
value	 ranges	 from	 10.78	 to	 33.82	 µM.	 For	 cell	 line	 A‐549,	
compound	 7d	 and	 7c	 are	 active	 with	 IC50	 value	 of	 10.82	
and10.78	 µM,	 respectively.	 Compound	7b	 is	 less	 active	 with	
IC50	 value	 of	 33.82	 µM.	 Similar	 results	 are	 obtained	 with	
remaining	cell	lines.	Compound	7d	having	IC50	values	of	10.99,	
12.36	 and	 19.52	 µM	 in	 HeLa,	 MCF‐7	 and	 DU‐145	 cell	 lines,	
respectively.	 The	 compound	 7c	 is	 active	 in	 A‐549	 and	 also	
HeLa,	MCF‐7	 and	DU‐145	 cell	 lines	with	 IC50	 values	 of	10.78,	
13.82	and	14.72	µM,	respectively.	 In	all	 the	four	cell	 lines	the	
compounds	 having	 phenyl	 sulfonamide	 ring	 (Compound	 4a	
and	7a)	are	moderately	active	with	IC50	values	from	22.72		to	
28.86	 µM,	 respectively.	 Compounds	 having	 para‐methyl	
phenyl	 sulfonamide	 ring	 (compound	 4b	 and	 7b)	 are	 most	
inactive	with	 IC50	 value	 20.36	 to	 33.82	 µM,	 respectively.	 The	
compound	 having	 only	 methyl	 sulfonamide	 ring	 (compound	
4e	and	7e)	is	having	moderate	IC50	values	from	14.38	to	23.86	
µM,	respectively.	The	compound	4e	is	most	active	in	HeLa	cell	
line	(ATCC	CCL‐2)	with	IC50	value	of	14.38	µM,	compare	to	it	is	
inactive	 with	 remaining	 cell	 lines.	 Interestingly	 compounds	
having	 electron	 withdrawing	 group	 at	 para	 position	 of	
aromatic	ring	are	most	active	on	all	 four	cell	lines	and	that	of	
electron	donating	groups	are	less	active	on	all	cell	lines.	If	we	
replace	 aromatic	 ring	 with	 methane	 sulfonamide	 then	 also	
activity	 is	 less	compared	 to	aromatic	substitutions.	These	are	
results	 from	 both	 series	 of	 compounds.	 There	 is	 not	 much	
difference	 in	 their	 inhibitions	 in	 all	 four	 cancer	 cell	 lines.	
Further	 we	 have	 studied	 the	most	 active	 compounds	4d,	7c	
and	7d	on	human	kinases.	
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Table	4	Inhibitory	activity	of	compound	4d,	7c	and	7d	against	panel	of	eight	human	kinases.	
Kinase	 %	Inhibition	(Compound	4d)	 %	Inhibition	(Compound	7c)	 %	Inhibition	(Compound	7d)	
Aurora‐A	 33	 34 31	
Aurora‐B	 31	 30 37	
CDK2/cyclinA	 28	 37	 43	
CDK2/cyclinE	 17	 12	 11	
CDK5/P25	 66	 59	 70	
EGFR	 4	 21	 15	
mTOR	 34	 38 36	
PDK1	 13	 21 9	
	
	
The	most	active	compounds	4d,	7c	and	7d	were	tested	for	
its	 activity	 against	 a	 panel	 of	 eight	 human	 kinase	 at	 10	 µM	
concentrations.	 The	 results	 are	 summarized	 in	 Table	 4.	 The	
compounds	 4d	 and	 7d	 having	 electron	 withdrawing	 group	
shows	very	promising	activity	against	CDK5/P25	kinase	with	
66	 and	 70%	 inhibitions,	 respectively.	 Compound	 7c	 also	
shows	promising	activity	of	59%	inhibition.	For	remaining	all	
the	 kinases	 Aurora‐A,	 Aurora‐B,	 mTOR	 and	 CDK/cyclinA	
shows	moderate	activity	in	the	range	of	28	to	43%	inhibitions.	
For	 remaining	 kinase	 CDK/cyclinE,	 PDK1	 and	 EGFR	 the	
activity	is	poor	in	the	range	of	4	to	21%	inhibitions.	
From	all	above	IC50	values	and	the	%	inhibitions	study,	the	
SAR	 can	be	 explained	on	 the	basis	 of	 substitutions	 on	 the	R1	
position	 with	 aromatic	 or	 aliphatic	 substitution.	 The	 com‐
pounds	containing	electron	withdrawing	groups	on	R1	phenyl	
ring	 show	 good	 to	 moderate	 activity	 (Compound	 4c,	 4d,	 7c	
and	7d)	when	compared	with	the	other	simple	substitution	on	
R1	 phenyl	 ring.	 Very	 low	 activity	 is	 observed	 with	 the	
substitution	of	electron	donating	methyl	group	on	the	phenyl	
ring.	
	
4.	Conclusion	
	
This	 reported	 work	 deals	 with	 the	 non‐asymmetric	
synthesis	 of	 benzoxazine	 derivatives	 and	 their	 evaluation	 as	
antiproliferative	agents	against	different	cancer	 cell	 lines	and	
in	 the	 growth	 of	 eight	 human	 kinases.	 The	 obtained	 yields	
were	good	to	excellent	with	high	purity.	The	compounds	were	
synthesized	on	gram	scale	by	using	series	of	reactions	having	
reduction	 and	 coupling	 reactions.	We	 have	 optimized	 all	 the	
reaction	steps	for	getting	good	yields.	The	compounds	4c,	4d,	
7c	 and	7d	were	 found	 to	 be	most	 active	 on	 the	 treated	 cell	
lines,	and	compound	4d,	7c	and	7d	shows	promising	activity	
against	CDK5/P25	kinase	inhibitors.	
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